# China SXT Pharmaceuticals, Inc. (SXTC)

Source page: https://stoqly.net/companies/sxtc

- **Ticker:** SXTC (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001723980
- **Latest annual report:** 20-F filed 2026-07-01 (https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $3.25 on 2026-10-30
- **Market cap:** $2.2M
- **EPS, trailing 12 months:** −$9.13
- **Revenue (FY2026):** $1.1M
- **Revenue growth:** −34.6%
- **Revenue growth, 5-year CAGR:** −24.9%
- **Gross margin:** 21.9%
- **Operating margin:** −625.9%
- **Net margin:** −545.2%
- **Return on invested capital:** −222.3%
- **Return on equity:** −27.5%
- **Net debt:** −$27.2M
- **Change in share count:** +7,053.7%
- **Piotroski F-score:** 4/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/sxtc/figures.csv

| US$ millions | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 5 | 7 | 7 | 5 | 5 | 3 | 2 | 2 | 2 | 1 |
| Operating income | 2 | 2 | 2 | -1 | -2 | -5 | -6 | -3 | -3 | -7 |
| Net income | 1 | 1 | 2 | -10 | -3 | -6 | -6 | -3 | -3 | -6 |
| Diluted EPS (US$) | 0.06 | 0.06 | 0.08 | 1.66 | -3.82 | -137.92 | -177.84 | -4,285.66 | -348.17 | -9.13 |
| Operating cash flow | 0 | 2 | 0 | 1 | -1 | 0 | 0 | -2 | -2 | -4 |
| Free cash flow | 0 | 1 | 0 | 1 | — | — | — | -2 | -2 | — |
| Cash | 0 | 1 | 9 | 7 | 13 | 16 | 17 | 12 | 18 | 28 |
| Debt and leases | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.